BIOTEST AKTIENGESELLSCHAFT – Trademark Portfolio

Entity Type: 03

BIOTEST AKTIENGESELLSCHAFT holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 3 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include SERACLONE. The owner is based in Dreieich.

Landsteinerstrasse 5

Dreieich 63303 , DE

4 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

BIOTEST AKTIENGESELLSCHAFT's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

1
Chemicals (3 filings)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

5
Pharmaceuticals (3 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does BIOTEST AKTIENGESELLSCHAFT have?

BIOTEST AKTIENGESELLSCHAFT has 4 U.S. trademarks filed with the USPTO. Of these, 1 registered, 3 cancelled.

What trademark classes does BIOTEST AKTIENGESELLSCHAFT file in?

BIOTEST AKTIENGESELLSCHAFT files trademarks across 2 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.

What are BIOTEST AKTIENGESELLSCHAFT's most well-known trademarks?

BIOTEST AKTIENGESELLSCHAFT's registered trademark portfolio includes well-known marks such as SERACLONE. These are among 1 currently registered trademark in the portfolio.

What is BIOTEST AKTIENGESELLSCHAFT's trademark registration success rate?

BIOTEST AKTIENGESELLSCHAFT has a 25% trademark registration rate, with 1 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.